Environmental or self-antigens and homotypic interactions induce BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other signals from your microenvironment and rising the activation of anti-apoptotic and proliferation pathways.Duvelisib was the second PI3K inhibitor authorised with the FDA, also based on a phase II